PL2316431T3 - Kompozycja w postaci stałego preparatu do stosowania doustnego obejmująca agonistę receptora S1P i alkohol cukrowy - Google Patents
Kompozycja w postaci stałego preparatu do stosowania doustnego obejmująca agonistę receptora S1P i alkohol cukrowyInfo
- Publication number
- PL2316431T3 PL2316431T3 PL10184951.1T PL10184951T PL2316431T3 PL 2316431 T3 PL2316431 T3 PL 2316431T3 PL 10184951 T PL10184951 T PL 10184951T PL 2316431 T3 PL2316431 T3 PL 2316431T3
- Authority
- PL
- Poland
- Prior art keywords
- receptor agonist
- sugar alcohol
- oral composition
- solid oral
- solid
- Prior art date
Links
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 title 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 150000005846 sugar alcohols Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Surgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46121503P | 2003-04-08 | 2003-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2316431T3 true PL2316431T3 (pl) | 2016-09-30 |
Family
ID=32326722
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04725895T PL1613288T3 (pl) | 2003-04-08 | 2004-04-06 | Stała kompozycja farmaceutyczna zawierająca agonistę receptora S1P oraz alkohol cukrowy |
| PL10184951.1T PL2316431T3 (pl) | 2003-04-08 | 2004-04-06 | Kompozycja w postaci stałego preparatu do stosowania doustnego obejmująca agonistę receptora S1P i alkohol cukrowy |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04725895T PL1613288T3 (pl) | 2003-04-08 | 2004-04-06 | Stała kompozycja farmaceutyczna zawierająca agonistę receptora S1P oraz alkohol cukrowy |
Country Status (41)
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1773307E (pt) * | 2004-07-30 | 2015-01-14 | Novartis Ag | Formulações de compostos à base de 2-amino-1,3- propanodiol |
| CN1891212B (zh) * | 2005-07-07 | 2010-10-13 | 马启明 | 一种口服制剂及其制备方法 |
| RU2493840C2 (ru) * | 2005-09-09 | 2013-09-27 | Новартис Аг | Лечение аутоиммунных заболеваний |
| ES2415756T3 (es) | 2005-11-09 | 2013-07-26 | Onyx Therapeutics, Inc. | Compuestos para la inhibición de enzimas |
| TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
| ES2415632T3 (es) | 2006-06-19 | 2013-07-26 | Onyx Therapeutics, Inc. | Epoxicetonas peptídicas para la inhibición del proteosoma |
| GB0612721D0 (en) | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
| EP1923055A1 (en) * | 2006-09-26 | 2008-05-21 | Novartis AG | Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator |
| PT3103448T (pt) * | 2006-09-26 | 2019-07-12 | Novartis Ag | Composições farmacêuticas que compreendem um modulador de s1p |
| EP1905434A1 (en) * | 2006-09-26 | 2008-04-02 | Novartis AG | Organic compounds comprising an S1P receptor agonist and their therapeutic use |
| EP1923054A1 (en) * | 2006-09-26 | 2008-05-21 | Novartis AG | Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator |
| AU2011235934A1 (en) * | 2006-09-26 | 2011-11-03 | Novartis Ag | Pharmaceutical compositions comprising an S1P modulator |
| EP1923058A1 (en) * | 2006-09-26 | 2008-05-21 | Novartis AG | Coated pharmaceutical composition comprising an S1P agonist or modulator |
| WO2008124210A1 (en) * | 2007-02-14 | 2008-10-16 | Emory University | Methods and compositions for treating or preventing infection using leukocyte sequestration agents |
| FI2140867T4 (fi) | 2007-03-29 | 2023-09-14 | Farmaseuttinen koostumus | |
| EP2207791B2 (en) | 2007-10-04 | 2019-08-07 | Onyx Therapeutics, Inc. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
| AR068986A1 (es) * | 2007-10-12 | 2009-12-23 | Novartis Ag | Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p) |
| AU2012216630B2 (en) * | 2007-10-12 | 2015-01-22 | Novartis Ag | Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators |
| JP5534645B2 (ja) * | 2008-01-11 | 2014-07-02 | 日医工株式会社 | 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤 |
| JP5452237B2 (ja) | 2008-02-07 | 2014-03-26 | 杏林製薬株式会社 | アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤 |
| PT2278960T (pt) | 2008-03-17 | 2017-03-09 | Actelion Pharmaceuticals Ltd | Regime de dosagem para um agonista seletivo do recetor s1p1 |
| KR20110020928A (ko) | 2008-06-20 | 2011-03-03 | 노파르티스 아게 | 다발성 경화증을 치료하기 위한 소아용 조성물 |
| JP5756749B2 (ja) * | 2008-06-20 | 2015-07-29 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 直接圧縮性および迅速崩壊性錠剤マトリックス |
| CN102143692A (zh) * | 2008-09-04 | 2011-08-03 | 卡吉尔公司 | 赤藓醇的压片 |
| EA024364B1 (ru) | 2008-10-21 | 2016-09-30 | Оникс Терапьютикс, Инк. | Способ лечения множественной миеломы |
| AU2013100531B4 (en) * | 2008-11-11 | 2013-11-28 | Novartis Ag | Crystalline forms of fingolimod HCL |
| AU2009315736B2 (en) * | 2008-11-11 | 2013-08-29 | Novartis Ag | Crystalline forms of fingolimod HCL |
| MX2011004924A (es) | 2008-11-11 | 2011-05-30 | Novartis Ag | Sales de fingolimod. |
| JP5305421B2 (ja) | 2008-12-17 | 2013-10-02 | 第一三共株式会社 | ジアミン誘導体の製造方法 |
| WO2010082531A1 (ja) | 2009-01-13 | 2010-07-22 | 第一三共株式会社 | 活性化血液凝固因子阻害剤 |
| JP5666424B2 (ja) | 2009-03-10 | 2015-02-12 | 第一三共株式会社 | ジアミン誘導体の製造方法 |
| ES2542237T3 (es) | 2009-03-13 | 2015-08-03 | Daiichi Sankyo Company, Limited | Procedimiento de producción de un derivado de diamina ópticamente activo |
| TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
| MY155256A (en) * | 2009-06-18 | 2015-09-30 | Daiichi Sankyo Co Ltd | Pharmaceutical composition having improved solubility |
| US9675566B2 (en) | 2009-07-16 | 2017-06-13 | Pathologica Llc | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing |
| WO2011060179A1 (en) | 2009-11-13 | 2011-05-19 | Onyx Therapeutics, Inc | Use of peptide epoxyketones for metastasis suppression |
| EP2542238B1 (en) | 2010-03-01 | 2015-08-12 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
| EP2548879B1 (en) | 2010-03-19 | 2015-12-09 | Daiichi Sankyo Company, Limited | Crystal of diamine derivative and method of producing same |
| EP2548556B1 (en) | 2010-03-19 | 2016-08-10 | Daiichi Sankyo Company, Limited | Method for improving dissolvability of anticoagulant |
| US20130095177A1 (en) * | 2010-04-22 | 2013-04-18 | Ratiopharm Gmbh | Method of preparing an oral dosage form comprising fingolimod |
| JP5780657B2 (ja) | 2010-07-02 | 2015-09-16 | 第一三共株式会社 | 光学活性ジアミン誘導体の塩の製造方法 |
| WO2012070059A1 (en) | 2010-11-25 | 2012-05-31 | Shilpa Medicare Limited | Fingolimod polymorphs and their processes |
| JO3619B1 (ar) | 2011-01-07 | 2020-08-27 | Novartis Ag | صياغات مثبطة للمناعة |
| NO2665471T3 (OSRAM) | 2011-01-19 | 2018-05-26 | ||
| AR085749A1 (es) | 2011-04-01 | 2013-10-23 | Novartis Ag | Formulaciones |
| EA028950B1 (ru) | 2011-08-01 | 2018-01-31 | Тева Фармасьютикал Индастриз Лтд. | Способ получения фармацевтических композиций, содержащих финголимод |
| EP2742941B1 (en) | 2011-08-10 | 2018-04-18 | Daiichi Sankyo Company, Limited | Pharmaceutical composition containing diamine derivative |
| WO2013091704A1 (en) | 2011-12-22 | 2013-06-27 | Synthon Bv | Pharmaceutical composition comprising fingolimod |
| RU2482842C1 (ru) * | 2012-04-26 | 2013-05-27 | Открытое акционерное общество "Новосибхимфарм" | Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения |
| RU2506949C1 (ru) * | 2012-06-13 | 2014-02-20 | Открытое акционерное общество "Новосибхимфарм" | Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний |
| UY34897A (es) | 2012-07-09 | 2014-01-31 | Onyx Therapeutics Inc | Profarmacos de inhibidores peptidicos de expoxi cetona proteasa |
| RU2496486C1 (ru) * | 2012-07-11 | 2013-10-27 | Александр Васильевич Иващенко | Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение |
| BR112015016189A8 (pt) | 2013-01-08 | 2019-10-22 | Pathologica Llc | usos de metilglioxal bis (guanilhidrazona) (mgbg), uso de metilglioxal bis (guanilhidrazona) (mgbg) e um agente e composição farmacêutica |
| WO2014141298A2 (en) * | 2013-03-11 | 2014-09-18 | Astron Research Limited | Stable pharmaceutical composition of fingolimod |
| ES2733920T3 (es) * | 2013-04-26 | 2019-12-03 | Univ Kyoto | Composición que comprende un agonista del receptor 1 de esfingosina-1-fosfato para inhibir la formación y/o el aumento de tamaño de un aneurisma cerebral o para reducirlo |
| WO2013190151A1 (en) * | 2013-05-13 | 2013-12-27 | Synthon B.V. | Pharmaceutical composition comprising fingolimod |
| WO2015015254A1 (en) * | 2013-07-29 | 2015-02-05 | Aizant Drug Research Solutions Pvt Ltd | Pharmaceutical compositions of fingolimod |
| RU2530626C1 (ru) * | 2013-10-21 | 2014-10-10 | Ооо "Валента-Интеллект" | Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний |
| US20170231928A1 (en) * | 2014-08-22 | 2017-08-17 | Sunshine Lake Pharma Co., Ltd. | Solid composition of fingolimod and preparation thereof |
| WO2016042493A1 (en) * | 2014-09-19 | 2016-03-24 | Aizant Drug Research Pvt. Ltd | Pharmaceutical compositions of fingolimod |
| WO2016118515A1 (en) * | 2015-01-20 | 2016-07-28 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
| US9925138B2 (en) | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
| US20180042895A1 (en) | 2015-02-26 | 2018-02-15 | Novartis Ag | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
| RU2577230C1 (ru) * | 2015-04-09 | 2016-03-10 | Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" | Способ получения капсул финголимода гидрохлорида |
| US9690975B2 (en) | 2015-05-28 | 2017-06-27 | Axogen Corporation | Quantitative structural assay of a nerve graft |
| US11434200B2 (en) | 2017-03-09 | 2022-09-06 | Novartis Ag | Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof |
| WO2018178744A1 (en) | 2017-03-29 | 2018-10-04 | Deva Holding Anonim Sirketi | Stable formulations of fingolimod |
| GR1009654B (el) | 2018-08-31 | 2019-11-18 | Φαρματεν Α.Β.Ε.Ε. | Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου |
| DE102018217334A1 (de) * | 2018-10-10 | 2020-04-16 | Harbins Ruhr Bioscience, Inc. | Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel |
| JP7503420B2 (ja) * | 2020-05-18 | 2024-06-20 | 東和薬品株式会社 | フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法 |
| EP4181906A1 (en) | 2020-07-16 | 2023-05-24 | Harbins Ruhr Bioscience, Inc. | Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection |
| CA3208122A1 (en) * | 2021-01-28 | 2022-08-04 | Priothera Sas | Methods of treatment with s1p receptor modulators |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7607683A (nl) * | 1976-07-12 | 1978-01-16 | Akzo Nv | Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan. |
| US4110332A (en) * | 1977-05-05 | 1978-08-29 | Chevron Research Company | 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones |
| US4559153A (en) | 1983-10-25 | 1985-12-17 | Phillips Petroleum Company | Metal working lubricant |
| US5112616A (en) * | 1988-11-30 | 1992-05-12 | Schering Corporation | Fast dissolving buccal tablet |
| JP2841857B2 (ja) * | 1990-11-29 | 1998-12-24 | 田辺製薬株式会社 | 長期間安定な経口用医薬製剤 |
| DK0627406T3 (da) | 1992-10-21 | 1999-07-12 | Taito Co | 2-Amino-1,3-propandiolforbindelser og immunundertrykkende midler |
| ATE211726T1 (de) | 1994-08-22 | 2002-01-15 | Welfide Corp | Benzolderivate und deren medizinische verwendung |
| RU2156127C2 (ru) | 1995-12-28 | 2000-09-20 | Еситоми Фармасьютикал Индустриз, Лтд. | Препарат местного применения для иммуносупрессии и лечения аутоиммунных или аллергических заболеваний |
| US6476004B1 (en) * | 1996-07-18 | 2002-11-05 | Mitsubishi Pharma Corporation | Pharmaceutical composition |
| JPH11209277A (ja) * | 1998-01-19 | 1999-08-03 | Yoshitomi Pharmaceut Ind Ltd | 医薬組成物 |
| JP2002241272A (ja) * | 1996-07-18 | 2002-08-28 | Mitsubishi Pharma Corp | 医薬処方組成物 |
| GB9624038D0 (en) | 1996-11-19 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| ES2317663T3 (es) * | 1997-02-27 | 2009-04-16 | Novartis Ag | Composicion farmaceutica que comprende 2-amino-2-(2-(4-octilfenil)etil)propano-1,3-diol, una lecitina y un sacarido. |
| DK1319651T3 (da) * | 1997-04-04 | 2005-08-01 | Mitsubishi Pharma Corp | 2-aminopropan-1,3-diolforbindelser, medicinsk anvendelse deraf og mellemprodukter til syntese af disse |
| JPH1180026A (ja) * | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| JP3545595B2 (ja) | 1998-04-01 | 2004-07-21 | 花王株式会社 | スフィンゴ糖脂質の製造法 |
| JP4627356B2 (ja) | 1999-06-30 | 2011-02-09 | 昭 松森 | ウイルス性心筋炎の予防または治療薬剤 |
| KR20020027463A (ko) * | 1999-07-12 | 2002-04-13 | 우에노 도시오 | 스핀고신-1-인산 수용체 아고니스트 또는스핀고신-1-인산을 유효 성분으로서 함유하는 선유화 억제제 |
| SK152003A3 (en) | 2000-07-13 | 2004-07-07 | Sankyo Co | Amino alcohol derivatives |
| JP2004507552A (ja) | 2000-08-31 | 2004-03-11 | メルク エンド カムパニー インコーポレーテッド | 免疫調節剤としてのリン酸誘導体 |
| US6953332B1 (en) | 2000-11-28 | 2005-10-11 | St. Jude Medical, Inc. | Mandrel for use in forming valved prostheses having polymer leaflets by dip coating |
| PL367348A1 (en) | 2001-03-26 | 2005-02-21 | Novartis Ag | 2-amino-propanol derivatives |
| US7521192B2 (en) | 2001-04-18 | 2009-04-21 | Rigel Pharmaceuticals, Inc. | EDG: modulators of lymphocyte activation and migration |
| JP2002316985A (ja) | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | ベンゾチオフェン誘導体 |
| US20040235794A1 (en) | 2001-09-04 | 2004-11-25 | Shinji Nakade | Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller |
| CA2460640C (en) | 2001-09-27 | 2011-03-29 | Kyorin Pharmaceutical Co., Ltd. | Diaryl ether derivatives, salts thereof and immunosuppressive agents using the same |
| JP4217620B2 (ja) | 2001-09-27 | 2009-02-04 | 杏林製薬株式会社 | ジアリールスルフィド誘導体とその付加塩及び免疫抑制剤 |
| WO2003061567A2 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
| CA2473740A1 (en) | 2002-01-18 | 2003-07-31 | David Solow-Cordero | Methods of treating conditions associated with an edg receptor |
| DE60330047D1 (en) | 2002-01-18 | 2009-12-24 | Merck & Co Inc | "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten" |
| AU2003207567B2 (en) | 2002-01-18 | 2008-01-24 | Merck Sharp & Dohme Corp. | Edg receptor agonists |
| SI1772145T1 (sl) * | 2004-07-16 | 2011-06-30 | Kyorin Seiyaku Kk | Postopek za učinkovito uporabo zdravila in postopek za preprečevanje stranskih učinkov |
-
2004
- 2004-04-06 GB GB0407819A patent/GB2400318B/en not_active Expired - Lifetime
- 2004-04-06 JP JP2004111761A patent/JP5495467B2/ja not_active Expired - Lifetime
- 2004-04-06 CA CA2707750A patent/CA2707750A1/en not_active Abandoned
- 2004-04-06 KR KR1020127019448A patent/KR101367574B1/ko not_active Expired - Lifetime
- 2004-04-06 PL PL04725895T patent/PL1613288T3/pl unknown
- 2004-04-06 NZ NZ586280A patent/NZ586280A/en not_active IP Right Cessation
- 2004-04-06 DE DE202004021680U patent/DE202004021680U1/de not_active Expired - Lifetime
- 2004-04-06 EP EP04725895A patent/EP1613288B1/en not_active Expired - Lifetime
- 2004-04-06 EP EP10184951.1A patent/EP2316431B1/en not_active Revoked
- 2004-04-06 ES ES200400852A patent/ES2228282B1/es not_active Expired - Fee Related
- 2004-04-06 DE DE102004016947A patent/DE102004016947A1/de not_active Ceased
- 2004-04-06 DK DK10184951.1T patent/DK2316431T3/en active
- 2004-04-06 CA CA2521325A patent/CA2521325C/en not_active Expired - Lifetime
- 2004-04-06 MX MXPA05010860A patent/MXPA05010860A/es active IP Right Grant
- 2004-04-06 HU HUE10184951A patent/HUE028247T2/en unknown
- 2004-04-06 AT AT04725895T patent/ATE414508T1/de active
- 2004-04-06 PE PE2015000303A patent/PE20150676A1/es not_active Application Discontinuation
- 2004-04-06 CN CN2010101213007A patent/CN101797241B/zh not_active Expired - Lifetime
- 2004-04-06 ES ES04725895T patent/ES2320767T3/es not_active Expired - Lifetime
- 2004-04-06 HR HR20100600A patent/HRP20100600A2/hr not_active Application Discontinuation
- 2004-04-06 ES ES10184951.1T patent/ES2556947T3/es not_active Expired - Lifetime
- 2004-04-06 PT PT04725895T patent/PT1613288E/pt unknown
- 2004-04-06 EP EP14163450.1A patent/EP2769713A1/en not_active Withdrawn
- 2004-04-06 FR FR0450692A patent/FR2854073B1/fr not_active Expired - Lifetime
- 2004-04-06 SI SI200431037T patent/SI1613288T1/sl unknown
- 2004-04-06 KR KR1020107029859A patent/KR20110005320A/ko not_active Ceased
- 2004-04-06 PE PE2008001684A patent/PE20090743A1/es not_active Application Discontinuation
- 2004-04-06 AR ARP040101162A patent/AR043987A1/es not_active Application Discontinuation
- 2004-04-06 DK DK04725895T patent/DK1613288T3/da active
- 2004-04-06 PL PL10184951.1T patent/PL2316431T3/pl unknown
- 2004-04-06 PE PE2013000382A patent/PE20131352A1/es active IP Right Grant
- 2004-04-06 CN CN2004800092370A patent/CN1767819B/zh not_active Expired - Lifetime
- 2004-04-06 RU RU2005134173/15A patent/RU2358716C2/ru not_active IP Right Cessation
- 2004-04-06 PE PE2012002027A patent/PE20130200A1/es not_active Application Discontinuation
- 2004-04-06 NZ NZ592339A patent/NZ592339A/xx not_active IP Right Cessation
- 2004-04-06 SG SG2008040545A patent/SG175449A1/en unknown
- 2004-04-06 BR BRPI0409250A patent/BRPI0409250B8/pt active IP Right Grant
- 2004-04-06 DE DE201112100047 patent/DE122011100047I1/de active Pending
- 2004-04-06 HR HR20050886A patent/HRP20050886B1/xx not_active IP Right Cessation
- 2004-04-06 US US10/552,005 patent/US20060275357A1/en not_active Abandoned
- 2004-04-06 GR GR20040100121A patent/GR1005052B/el unknown
- 2004-04-06 WO PCT/EP2004/003656 patent/WO2004089341A1/en not_active Ceased
- 2004-04-06 PE PE2004000355A patent/PE20050396A1/es not_active Application Discontinuation
- 2004-04-06 NZ NZ542622A patent/NZ542622A/xx not_active IP Right Cessation
- 2004-04-06 AU AU2004228929A patent/AU2004228929B2/en active Active
- 2004-04-06 EP EP08161161A patent/EP2008650A3/en not_active Withdrawn
- 2004-04-06 DE DE602004017847T patent/DE602004017847D1/de not_active Expired - Lifetime
- 2004-04-06 KR KR1020057019066A patent/KR20050121712A/ko not_active Ceased
- 2004-04-06 EP EP10186307A patent/EP2319502A1/en not_active Withdrawn
- 2004-04-06 AT ATA606/2004A patent/AT501681B1/de not_active IP Right Cessation
- 2004-04-06 SI SI200432283T patent/SI2316431T1/sl unknown
- 2004-04-06 HR HRP20100601AA patent/HRP20100601B1/hr not_active IP Right Cessation
- 2004-04-06 IT IT000682A patent/ITMI20040682A1/it unknown
- 2004-04-07 CL CL200400745A patent/CL2004000745A1/es unknown
- 2004-04-07 MY MYPI20041275A patent/MY141249A/en unknown
- 2004-04-07 TW TW093109631A patent/TWI332847B/zh active
- 2004-04-07 BE BE2004/0180A patent/BE1015972A5/fr not_active IP Right Cessation
-
2005
- 2005-09-14 ZA ZA200507394A patent/ZA200507394B/en unknown
- 2005-09-15 IL IL170888A patent/IL170888A/en active IP Right Grant
- 2005-10-07 TN TNP2005000256A patent/TNSN05256A1/en unknown
- 2005-10-07 EC EC2005006090A patent/ECSP056090A/es unknown
- 2005-10-19 MA MA28560A patent/MA27729A1/fr unknown
- 2005-11-01 IS IS8114A patent/IS2682B/is unknown
- 2005-11-07 NO NO20055231A patent/NO329332B1/no active Protection Beyond IP Right Term
-
2008
- 2008-05-08 AT AT0074408A patent/AT504853A2/de not_active Application Discontinuation
- 2008-08-11 US US12/189,323 patent/US8324283B2/en not_active Expired - Fee Related
- 2008-08-13 US US12/191,098 patent/US20090203798A1/en not_active Abandoned
-
2009
- 2009-02-17 RU RU2009105403/15A patent/RU2009105403A/ru not_active Application Discontinuation
- 2009-02-19 CY CY20091100192T patent/CY1110260T1/el unknown
- 2009-03-12 IL IL197578A patent/IL197578A/en active IP Right Grant
-
2010
- 2010-02-18 NO NO20100250A patent/NO334116B1/no unknown
- 2010-02-25 IS IS8885A patent/IS8885A/is unknown
- 2010-08-25 JP JP2010188835A patent/JP5543298B2/ja not_active Expired - Lifetime
- 2010-10-26 AR ARP100103931A patent/AR078782A2/es not_active Application Discontinuation
- 2010-10-26 AR ARP100103930A patent/AR078781A2/es not_active Application Discontinuation
- 2010-11-17 RU RU2010146697/15A patent/RU2475236C2/ru active
- 2010-11-18 RU RU2010147000/15A patent/RU2475237C2/ru active
-
2011
- 2011-01-10 US US12/987,726 patent/US20110105620A1/en not_active Abandoned
- 2011-03-01 CL CL2011000450A patent/CL2011000450A1/es unknown
- 2011-09-06 HU HUS1100016C patent/HUS1100016I1/hu unknown
- 2011-09-08 LU LU91867C patent/LU91867I2/fr unknown
- 2011-09-08 FR FR11C0036C patent/FR11C0036I2/fr active Active
- 2011-09-08 CY CY2011013C patent/CY2011013I2/el unknown
- 2011-09-08 NO NO2011016C patent/NO2011016I2/no unknown
- 2011-09-08 BE BE2011C030C patent/BE2011C030I2/fr unknown
-
2012
- 2012-11-15 RU RU2012148593/15A patent/RU2012148593A/ru not_active Application Discontinuation
- 2012-12-20 US US13/721,278 patent/US20130108675A1/en not_active Abandoned
-
2013
- 2013-04-23 JP JP2013090602A patent/JP2013177404A/ja active Pending
- 2013-09-16 US US14/027,943 patent/US20140011885A1/en not_active Abandoned
- 2013-09-26 NO NO20131287A patent/NO335120B1/no unknown
-
2014
- 2014-05-23 US US14/285,808 patent/US20140255497A1/en not_active Abandoned
-
2015
- 2015-10-12 IL IL242037A patent/IL242037A0/en unknown
- 2015-12-29 CY CY20151101194T patent/CY1117071T1/el unknown
-
2017
- 2017-06-27 US US15/634,579 patent/US20170290787A1/en not_active Abandoned
-
2019
- 2019-02-13 US US16/274,357 patent/US20190175527A1/en not_active Abandoned
-
2020
- 2020-04-03 US US16/839,703 patent/US20200237690A1/en not_active Abandoned
-
2021
- 2021-10-14 US US17/501,173 patent/US20220031609A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2316431T3 (pl) | Kompozycja w postaci stałego preparatu do stosowania doustnego obejmująca agonistę receptora S1P i alkohol cukrowy | |
| SI2277521T1 (sl) | Oralne formulacije opioidnih agonistov, varne pred zlorabo | |
| IL169902A0 (en) | Sugar-free oral transmucosal solid dosage forms and uses thereof | |
| EP1701691A4 (en) | METHODS AND COMPOSITIONS FOR ORAL HYGIENE | |
| ZA200508733B (en) | Muscarinic M1 receptor agonists for pain management | |
| PL377495A1 (pl) | Stały lek do stosowania doustnego | |
| PL1797871T3 (pl) | Długo działający preparat o przedłużonym uwalnianiu zawierający agonistę receptora dopaminowego i sposób jego wytwarzania | |
| GB0330255D0 (en) | Multiparticulate formulations for oral delivery | |
| EP1757273A4 (en) | PREPARATION FOR ORAL ADMINISTRATION | |
| IL161997A (en) | Pharmaceutical composition comprising a 5ht1 receptor agonist | |
| AU2003252683A8 (en) | Composition for oral use | |
| IL177826A0 (en) | Oral matrix formulations comprising licarbazepine | |
| GB0325383D0 (en) | Oral formulations | |
| EP1755477A4 (en) | MOUTH HYGIENE COMPOSITIONS AND METHOD OF USE THEREOF | |
| GB2403407B (en) | Palatable oral anthelmintic composition | |
| IL178296A0 (en) | Pharmaceutical compositions containing a gaba?? receptor agonist | |
| PL377147A1 (pl) | Doustna kompozycja | |
| AU2003280065A1 (en) | Bupropion hydrochloride solid dosage forms | |
| HK1071685B (en) | Pharmaceutical composition comprising an s1p receptor agonist | |
| HK1100897A (en) | Oral matrix formulations comprising licarbazepine | |
| PL373776A1 (en) | Oral pharmaceutical compound | |
| GB0406393D0 (en) | Oral composition | |
| GB0406392D0 (en) | Oral composition | |
| HK1085673A (en) | Sugar-free oral transmucosal solid dosage forms and uses thereof | |
| GB0413138D0 (en) | Preparation for oral administration |